ledipasvir/sofosbuvir / Generic mfg. 
Welcome,         Profile    Billing    Logout  
 54 Diseases   8 Trials   8 Trials   2662 News 


«12345678910111213...2324»
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
    Clinical, Observational data, Journal:  Comparing direct acting antivirals for hepatitis C using observational data - Why and how? (Pubmed Central) -  Jul 1, 2021   
    This risk difference is evidence that SOF/LDV is not inferior to SOF/VEL for easy to treat patients with genotype 1 HCV. The approach is a template for comparing drugs when there are no data from comparative trials.
  • ||||||||||  Viekira Pak (ombitasvir/paritaprevir/ritonavir/dasabuvir) / AbbVie, Enanta Pharma
    Journal:  Discovery of hit molecules targeting allosteric site of hepatitis C virus NS5B polymerase. (Pubmed Central) -  Jun 22, 2021   
    Top 20 hits were screened out from identified hits using molecular docking technique. Four molecules, that are representative of 20 hits were evaluated for binding affinity under in vitro conditions using surface plasmon resonance based assay and the results emphasized that compound with CoCoCo ID: 412075 could exhibit good binding response toward NS5B and could be a potential candidate as NS5B inhibitor.
  • ||||||||||  ledipasvir/sofosbuvir / Generic mfg.
    Trial completion date, Trial primary completion date:  Harvoni in Patients With Chronic Hepatitis C Virus (HCV) Infection in Korea (clinicaltrials.gov) -  Jun 8, 2021   
    P=N/A,  N=3000, Recruiting, 
    37) Where do you want this patient to be dispositioned? Trial completion date: Oct 2021 --> Jan 2022 | Trial primary completion date: Oct 2021 --> Jan 2022
  • ||||||||||  Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    Clinical, Review, Journal:  Breakthroughs and challenges in the management of pediatric viral hepatitis. (Pubmed Central) -  Jun 8, 2021   
    Anti-HBV investigational compounds are reviewed in light of the pathophysiology in the pediatric population, including capsid assembly modulators, antigen secretion inhibitors, silencing RNAs, and immune modifiers. Recommendations for screening and management of immunosuppressed children or those with other risk factors or comorbidities are also summarized.
  • ||||||||||  ledipasvir/sofosbuvir / Generic mfg.
    [VIRTUAL] TREATMENT OF CHRONIC HEPATITIS C USING DIRECT ACTING ANTIVIRALS IN TEENAGERS WITH HIV COINFECTION. () -  Jun 2, 2021 - Abstract #ESPID2021ESPID_1446;    
    Background: No data on the efficacy, safety, and tolerability of ledipasvir/sofosbuvir (LDV/SOF) in children and adolescents with hepatitis C virus (HCV) and human immunodeficiency virus (HIV) coinfection are available...12- week treatment with LDV/SOF in two HIV/HCV-coinfected teenagers was safe and effective. Our experience may encourage other clinicians to start antiviral treatment with LDV/SOF in their patients.
  • ||||||||||  [VIRTUAL] LIVER INVOLVEMENT IN RHEUMATOID ARTHRITIS () -  May 21, 2021 - Abstract #EULAR2021EULAR_3025;    
    A careful monitoring of liver enzymes tests is crucial to detect hepatic disease and prevent its evolution to a chronic liver disease and cirrhosis. On the other hand, screening for viral hepatitis B and C is necessary to prevent an aggravation of a chronic infection and a reactivation of a latent one [2].
  • ||||||||||  Zepatier (grazoprevir/elbasvir) / Merck (MSD), Mavyret (glecaprevir/pibrentasvir) / AbbVie, Enanta Pharma
    [VIRTUAL] Successful Single-Center Experience Using HCV+ Organs for Single and Dual-Organ Transplantation () -  May 18, 2021 - Abstract #ATC2021ATC_1837;    
    We report successful single-center experience using HCV+ organs for both single and dual solid organ transplant. As experience using such organs for transplant continues to increase and long term follow-up is obtained, HCV+ donors may be routinely used to increase the organ donor pool.
  • ||||||||||  ledipasvir/sofosbuvir / Generic mfg.
    Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date:  Harvoni Treatment Porphyria Cutanea Tarda (clinicaltrials.gov) -  Apr 26, 2021   
    P2,  N=15, Active, not recruiting, 
    Georgia has made substantial progress in the path towards eliminating hepatitis C. Scaling-up testing and diagnosis, along with effective linkage to treatment services are needed to achieve the goal of elimination. Recruiting --> Active, not recruiting | N=49 --> 15 | Trial completion date: Aug 2024 --> Jul 2021 | Trial primary completion date: Aug 2023 --> Feb 2021
  • ||||||||||  sofosbuvir/velpatasvir / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
    [VIRTUAL] Progress towards achieving hepatitis C elimination in the country of Georgia, April 2015-December 2020 (Poster area) -  Apr 9, 2021 - Abstract #EASLILC2021EASL_ILC_1235;    
    Georgia has made substantial progress towards elimin- ating hepatitis C, with over 40% of personswith chronic HCV infection identified and cured. Efforts to identify and link to care persons with HCV infection, ensure SVR testing and implement prevention interventions are needed to achieve the elimination goals.
  • ||||||||||  ledipasvir/sofosbuvir / Generic mfg.
    Journal, HEOR:  Cost-effectiveness of Oral Regimens for Adolescents With Chronic Hepatitis C Virus Infection. (Pubmed Central) -  Apr 7, 2021   
    In the setting of good tolerability and high effectiveness of DAA therapy, alternative treatment approaches tailored to the target group such as less intense monitoring or in contrast, directly observed treatment (DOT) should be considered. Novel oral regimes for adolescents with HCV infection are likely to be cost-effective in the context of the United States and China.
  • ||||||||||  Technivie (ombitasvir/paritaprevir/ritonavir) / AbbVie
    Journal:  Loss to follow-up: a significant barrier in the treatment cascade with direct-acting therapies. (Pubmed Central) -  Mar 26, 2021   
    Our findings indicate that loss to follow up exceeds viral-failure in HCV DAA therapy and its rate varies significantly by genotype and treatment regimen. Depending on the etiology of lost to follow up, personalized case management for those with medical complications and supporting services among IDU are needed to achieve the full benefits of effective treatments.
  • ||||||||||  ribavirin / Generic mfg., ledipasvir/sofosbuvir / Generic mfg.
    Clinical, Observational data, Journal:  Treatment of Chronic Hepatitis C Genotype 3 With Ledipasvir and Sofosbuvir: An Observational Study. (Pubmed Central) -  Mar 23, 2021   
    Single tablet LED and SOF combination is safe and effective in genotype 3 patients without cirrhosis even without ribavirin. Being effective in genotype 3, the combination can be used as a pangenotypic drug in patients without cirrhosis.
  • ||||||||||  ledipasvir/sofosbuvir / Generic mfg.
    Clinical, Journal:  Suboptimal SVR rates in African patients with atypical Genotype 1 subtypes: implications for global elimination of Hepatitis C. (Pubmed Central) -  Mar 20, 2021   
    Six treatment failures occurred with sofosbuvir/ledipasvir compared to 1 failure on a PI-based regimen...The most common genotype of Hepatitis C in Europe and the United States is genotype 1a or 1b and most clinical trials focused on these genotypes. We report that in a group of African patients, most of them had unusual (non-1a/1b) genotype 1 subtypes, and that the cure rate in these unusual genotypes was lower than in genotypes 1a and 1b.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    [VIRTUAL] This Is (Not) the Way: A Rare Case of Mycobacterium Peregrinum () -  Mar 14, 2021 - Abstract #ATS2021ATS_3616;    
    After four days without improvement patient was broadened to meropenem with some improvement in symptoms but patient remained persistently hypoxic, therefore underwent bronchoscopy on hospital day 8...Patient was discharged on ertapenem, once susceptibilities were obtained patient was transitioned to moxifloxacin and Bactrim by infectious disease as an outpatient...Unfortunately, the exact burden of M. peregrinum and NTM infections overall both nationally and internationally are not known as they are not reportable diseases to either the Centers for Disease Control or World Health Organization. Due to the complexities of NTM infections, we recommend a multidisciplinary approach including pulmonary and infectious disease specialists.
  • ||||||||||  Sovaldi (sofosbuvir) / Gilead
    [VIRTUAL] Trading Sustained Virologic Response for Pulmonary Vascular Resistance: Growing Evidence of Pulmonary Arterial Hypertension Linked with Sofosbuvir () -  Mar 14, 2021 - Abstract #ATS2021ATS_2556;    
    Introduction: Interferon-free regimens such as Ledipasvir/Sofosbuvir (Harvoni) have demonstrated superior sustained virologic response (SVR) rates and fewer side effects compared to traditional therapies for Hepatitis C virus (HCV)...She was started on sildenafil with subsequent improvement in her functional capacity, and a repeat TTE three months later revealed an RVSP of 57 mmHg...These findings are consistent with other case studies describing the same HCV DAA-related adverse effects, thus contributing to the growing evidence of an association of sofosbuvir-based therapies and the development and/or worsening of PAH. Further consideration of these therapies ought to be accompanied by appropriate screening modalities and adjustment of treatment regimens to account for cardiopulmonary-related adverse effects.
  • ||||||||||  ledipasvir/sofosbuvir / Generic mfg.
    Journal, IO biomarker:  Reconstitution of T follicular helper-humoral immune axis with elimination of hepatitis C virus. (Pubmed Central) -  Mar 12, 2021   
    Here, we aimed to evaluate the immunological changes in global and HCV-specific CD4 + CXCR5 + T, CD4 + CXCR5-T and B cells in 20 HCV patients who achieved SVR with Sofosbuvir and Ledipasvir for 12 weeks and compared with 15 healthy controls (HC)...Importantly, frequencies of T cells were significantly associated with HCV RNA reduction, expansion of memory B and plasmablasts, while negatively associated with exhausted/regulatory B cells. Our results demonstrate that SVR with DAA therapy is effective in the reconstitution of phenotypic and functional abnormalities of T-B cell axis.